Celcuity, Inc. (NASDAQ:CELC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Celcuity, Inc. (NASDAQ:CELC) have been assigned a consensus recommendation of “Moderate Buy” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $152.0909.

CELC has been the subject of a number of research reports. Macquarie Infrastructure set a $160.00 price target on Celcuity in a research note on Thursday, May 28th. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research note on Thursday, May 28th. Wolfe Research reiterated an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Finally, Craig Hallum decreased their price target on Celcuity from $189.00 to $171.00 and set a “buy” rating for the company in a research note on Wednesday.

Celcuity News Summary

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $145 price target on Celcuity, and its longer-term forecasts still imply meaningful profitability potential by 2028-2030.
• Neutral Sentiment: The company also announced an upsized $500 million convertible senior notes offering due 2032, which improves funding for development but also raises dilution concerns for shareholders. Celcuity Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
• Neutral Sentiment: Celcuity expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients, a development that could broaden the market opportunity if the study continues to progress well. Celcuity Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates for Celcuity, including lower projections for FY2026, FY2027, FY2028, FY2029, and Q4 2026, signaling expectations for continued losses before eventual profitability.
• Negative Sentiment: Investor sentiment also appears to have been hurt by reports that Celcuity shares fell after trial results disappointed some investors, even though other coverage described the late-stage breast cancer data as potentially strong or “practice-changing.” ASCO26: Celcuity punished as trial disappoints investors

Insider Transactions at Celcuity

In related news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director directly owned 65,000 shares in the company, valued at approximately $9,144,200. This trade represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares of the company’s stock, valued at $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 37,000 shares of company stock valued at $5,111,950 over the last quarter. Insiders own 13.33% of the company’s stock.

Hedge Funds Weigh In On Celcuity

A number of large investors have recently bought and sold shares of CELC. Creative Planning bought a new position in Celcuity in the second quarter worth about $177,000. Rhumbline Advisers lifted its holdings in Celcuity by 1.2% in the second quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after acquiring an additional 503 shares during the last quarter. XTX Topco Ltd bought a new position in Celcuity in the second quarter worth about $169,000. Quantinno Capital Management LP lifted its holdings in Celcuity by 20.7% in the second quarter. Quantinno Capital Management LP now owns 243,042 shares of the company’s stock worth $3,245,000 after acquiring an additional 41,756 shares during the last quarter. Finally, Paloma Partners Management Co lifted its holdings in Celcuity by 285.8% in the second quarter. Paloma Partners Management Co now owns 82,137 shares of the company’s stock worth $1,097,000 after acquiring an additional 60,849 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Trading Down 4.5%

NASDAQ CELC opened at $88.28 on Friday. Celcuity has a 12 month low of $11.27 and a 12 month high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. The company has a market capitalization of $4.31 billion, a price-to-earnings ratio of -22.64 and a beta of 0.10. The company’s fifty day moving average price is $122.01 and its two-hundred day moving average price is $111.39.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. As a group, research analysts predict that Celcuity will post -3.69 earnings per share for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.